Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.44 |
| ▸ | HRH1 | P35367 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4159913 | 0.98 | OPRM1 (0.43) | OPRM1HRH1MEN1KMT2AHTR2A | |
| SCHEMBL5633486 | 0.86 | DPP4 (0.51) | OPRM1HRH1MEN1KMT2AHTR2A | |
| SCHEMBL5969007 | 0.85 | HRH1 (0.44) | OPRM1HRH1MEN1KMT2AHTR2A | |
| SCHEMBL8477448 | 0.83 | L3MBTL3 (0.46) | OPRM1HRH1MEN1KMT2AHTR2A | |
| SCHEMBL16759363 | 0.82 | SLC6A9 (0.46) | OPRM1HRH1MEN1KMT2AHTR2A | |
| SCHEMBL8473371 | 0.81 | L3MBTL3 (0.56) | OPRM1HRH1MEN1KMT2AHTR2A | |
| SCHEMBL72670 | 0.81 | MEN1 (0.48) | OPRM1HRH1MEN1KMT2AHTR2A | |
| SCHEMBL14141067 | 0.81 | OPRM1 (0.44) | OPRM1HRH1MEN1KMT2AHTR2A | |
| SCHEMBL85392 | 0.81 | OPRM1 (0.48) | OPRM1HRH1MEN1KMT2AHTR2A | |
| Hydrochloric Acid SCHEMBL3552812 | 0.79 | MEN1 (0.47) | OPRM1HRH1MEN1KMT2AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240051985-A1 | METTL3 MODULATORS | ACCENT THERAPEUTICS INC (US) | 2024-02-15 | — | — | US | disclosed |
| CN-117098767-A | METTL3 modulators | 埃克森特治疗公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-110520422-A | Novel pyridone carboxylic acid derivatives or its salt | WAKUNAGA PHARMA CO LTD | 2019-11-29 | — | — | CN | disclosed |
| CN-104918615-B | The method for treating hepatopathy | 扎夫根股份有限公司 | 2018-10-12 | — | — | CN | disclosed |
| US-10064839-B2 | Methods of treating liver diseases | ZAFGEN, INC. (US) | 2018-09-04 | — | — | US | disclosed |
| US-20180002307-A1 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2018-01-04 | — | — | US | disclosed |
| US-20170326099-A1 | METHODS OF TREATING LIVER DISEASES | ZAFGEN, INC. | 2017-11-16 | — | — | US | disclosed |
| CN-107108625-A | Spirocyclic derivatives | 克罗诺斯治疗有限公司 | 2017-08-29 | — | — | CN | disclosed |
| US-9617237-B2 | Partially saturated tricyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9561209-B2 | Methods of treating liver diseases | ZAFGEN, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-5410057-A | 1-heteroarylazetidines and -pyrrolidines | SANOFI (FR) | 1995-04-25 | — | — | US | disclosed |
| WO-1994029336-A1 | NEW PEPTIDE DERIVATIVES | ASTRA AKTIEBOLAG (SE) | 1994-12-22 | — | — | WO | disclosed |
| EP-0591030-A2 | 1-Heteroaryl-azetidines and -pyrrolidines as 5-HT3 agonists | SANOFI (FR) | 1994-04-06 | — | — | EP | disclosed |
| US-4777175-A | (NAPHTHYRIDINE, QUINOLINE) CARBOXYLIC ACID | WARNER-LAMBERT COMPANY (US) | 1988-10-11 | — | — | US | disclosed |
| US-4771054-A | QUINOLINE CARBOXYLIC ACID | WARNER-LAMBERT COMPANY (US) | 1988-09-13 | — | — | US | disclosed |
| EP-0106489-B1 | ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1988-07-27 | — | — | EP | disclosed |
| US-4665079-A | QUINOLINE DERIVATIVES | WARNER-LAMBERT COMPANY (US) | 1987-05-12 | — | — | US | disclosed |
| US-4638067-A | NAPHTHYRIDINE AND QUINOLINE CARBOXYLIC ACIDS | WARNER-LAMBERT CO. (US) | 1987-01-20 | — | — | US | disclosed |
| EP-0153163-A2 | 7-Substituted-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids; 7-substituted-1-cyclopropyl-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acids; their derivatives; and a process for preparing the compounds | WARNER-LAMBERT COMPANY (US) | 1985-08-28 | — | — | EP | disclosed |
| EP-0106489-A2 | Antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1984-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240051985-A1 | METTL3 MODULATORS | METTL3, METTL16, METTL14 | OPRM1 634/4885HRH1 4167/4885MEN1 2437/4885 |
| US-20170326099-A1 | METHODS OF TREATING LIVER DISEASES | ENPEP, GOT2, METAP2 | OPRM1 2518/4885HRH1 1636/4885MEN1 4063/4885 |
| US-10064839-B2 | Methods of treating liver diseases | ENPEP, GOT2, METAP2 | OPRM1 2518/4885HRH1 1636/4885MEN1 4063/4885 |
| US-20180002307-A1 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | DNPEP, CES2, AADAC | OPRM1 801/4885HRH1 2373/4885MEN1 2282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.